ERBB2 and neoplasm: A pooled analysis of four prospective neoadjuvant clinical trials [2] and another cohort study using data from a prospectively maintained institutional database [14] described significantly longer DFS and OS for patients with HER2-low tumor than that for patients with HER2-zero tumor.